BridgeBio Pharma (BBIO) Enterprise Value (2017 - 2026)
BridgeBio Pharma recorded quarterly Enterprise Value of -$929.7 million in Q1 2026, down 61.17% quarter-over-quarter from -$576.9 million in Q4 2025, and down 75.21% year-over-year from -$3.8 billion in Q1 2025.
BridgeBio Pharma's Enterprise Value history runs 10 years deep, the most recent figure standing at -$929.7 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 75.21% year-over-year to -$929.7 million; the TTM figure through Mar 2026 stood at -$929.7 million (down 75.21% YoY), while the FY2025 annual figure was -$576.9 million, up 14.02% from the prior year.
- Enterprise Value came in at -$929.7 million for Q1 2026 at BridgeBio Pharma, down from -$576.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$255.4 million in Q3 2024 to a low of -$929.7 million in Q1 2026.
- A 5-year average of -$523.2 million and a median of -$530.6 million in 2025 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value soared 54.13% in 2023 and sank 75.21% in 2026, its largest moves.
- BridgeBio Pharma's Enterprise Value stood at -$403.3 million in 2022, then decreased by 5.03% to -$423.6 million in 2023, then tumbled by 58.38% to -$671.0 million in 2024, then gained by 14.02% to -$576.9 million in 2025, then plunged by 61.17% to -$929.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$929.7 million, -$576.9 million, and -$276.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -3.01 Bn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -929.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -929.75 Mn |
| Dec 31, 2025 | -576.88 Mn |
| Sep 30, 2025 | -276.02 Mn |
| Jun 30, 2025 | -747.01 Mn |
| Mar 31, 2025 | -530.64 Mn |
| Dec 31, 2024 | -670.95 Mn |
| Sep 30, 2024 | -255.44 Mn |
| Jun 30, 2024 | -536.31 Mn |
| Mar 31, 2024 | -463.08 Mn |
| Dec 31, 2023 | -423.64 Mn |
| Sep 30, 2023 | -492.81 Mn |
| Jun 30, 2023 | -310.32 Mn |
| Mar 31, 2023 | -420.62 Mn |
| Dec 31, 2022 | -403.34 Mn |
| Sep 30, 2022 | -547.88 Mn |
| Jun 30, 2022 | -676.55 Mn |
| Mar 31, 2022 | -633.48 Mn |
| Dec 31, 2021 | -390.54 Mn |
| Sep 30, 2021 | -596.64 Mn |
| Jun 30, 2021 | -835.80 Mn |
| Mar 31, 2021 | -917.85 Mn |
| Dec 31, 2020 | 1.35 Mn |
| Sep 30, 2020 | -708.11 Mn |
| Jun 30, 2020 | -839.03 Mn |
| Mar 31, 2020 | -902.12 Mn |
| Dec 31, 2019 | -361.53 Mn |
| Sep 30, 2019 | -533.48 Mn |
| Jun 30, 2019 | -293.63 Mn |
| Mar 31, 2019 | -372.83 Mn |
| Dec 31, 2018 | -435.96 Mn |
| Sep 30, 2018 | -210.81 Mn |
| Jun 30, 2018 | -249.19 Mn |
| Dec 31, 2017 | -91.16 Mn |